Ozempic, Saxenda, Rybelsus

In 2024, injectables for weight loss are increasingly popular, with options like Ozempic, Saxenda, and Rybelsus leading the way. These injectables are classified as glucagon-like peptide 1 (GLP-1) receptor agonists, which effectively suppress appetite and aid in weight reduction by promoting a calorie deficit. Da Vinci Medical offers these advanced injectable treatments, providing effective solutions for individuals looking to manage their weight effectively.

Ozempic (Semaglutide) is a glucagon-like peptide 1 (GLP-1) receptor agonist recommended as an adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes mellitus. It also helps reduce the risk of major heart disease in adults. Administered through weekly injections, Ozempic offers a convenient treatment option for managing diabetes effectively.

Saxenda (Liraglutide) is a glucagon-like peptide 1 (GLP-1) receptor agonist prescribed alongside a reduced-calorie diet and increased physical activity. It is administered via daily injection, with doses starting at 0.6mg and escalating to 3.0mg as recommended.

At Da Vinci Medical, we offer advanced treatments such as Ozempic, Saxenda, and Rybelsus, which are glucagon-like peptide 1 (GLP-1) receptor agonists.

These medications are used adjectively with diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Ozempic is administered once weekly via injection, Saxenda requires daily injection with doses starting at 0.6mg and escalating up to 3.0mg, and Rybelsus is taken orally once daily with doses ranging from 3mg to 14mg. These options cater to individual preferences and ensure effective management of diabetes at Da Vinci Medical.